

**In the claims**

**This listing of claims will replace all prior versions, and listings, of claims in the application:**

- 1-18. (Cancelled).
19. (Withdrawn) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
- (a) determining the presence or amount of expression of the polypeptide of claim [[11]] 56 in a biological sample; and
  - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
20. (Currently Amended) A method for identifying a binding partner to the polypeptide of claim [[11]] 56 comprising:
- (a) contacting the polypeptide of claim [[11]] 56 with a binding partner; and
  - (b) determining whether the binding partner effects an activity of the polypeptide.
- 21-29. (Cancelled).
30. (Currently Amended) An isolated protein comprising the amino acid sequence of the [[complete]] secreted portion of the polypeptide encoded by the HHEPU32 cDNA contained in ATCC Deposit No. 209603.
31. (Previously Presented) The isolated protein of claim 30 which comprises the amino acid sequence of the complete polypeptide encoded by the HHEPU32 cDNA contained in ATCC Deposit No. 209603, excepting the N-terminal methionine.

32. (Currently Amended) The isolated protein of claim 30 which comprises the amino acid sequence of the [[secreted portion of the]] complete polypeptide encoded by the HHEPU32 cDNA contained in ATCC Deposit No. 209603.
33. (Previously Presented) The protein of claim 30 which further comprises a polypeptide sequence heterologous to the HHEPU32 cDNA contained in ATCC Deposit No. 209603.
34. (Previously Presented) A composition comprising the protein of claim 30 and an acceptable carrier.
35. (Previously Presented) An isolated protein produced by the method comprising:  
(a) expressing the protein of claim 30 by a cell; and  
(b) recovering said protein.
- 36-40. (Cancelled).
41. (Previously Presented) An isolated first polypeptide at least 90% identical to a second polypeptide consisting of the complete polypeptide encoded by the HHEPU32 cDNA contained in ATCC Deposit No. 209603.
42. (Previously Presented) The isolated polypeptide of claim 41, wherein said first polypeptide is at least 95% identical to said second polypeptide.
43. (Previously Presented) The protein of claim 41 which further comprises a polypeptide sequence heterologous to the HHEPU32 cDNA contained in ATCC Deposit No. 209603.
44. (Previously Presented) A composition comprising the protein of claim 41 and an acceptable carrier.
45. (Previously Presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 41 by a cell; and
- (b) recovering said protein.

46-50. (Cancelled).

- 51. (Previously Presented) An isolated protein consisting of a fragment of the complete polypeptide encoded by the HHEPU32 cDNA contained in ATCC Deposit No. 209603, wherein said fragment is at least 30 contiguous amino acid residues in length.
- 52. (Previously Presented) The isolated protein of claim 51, wherein said fragment is at least 50 contiguous amino acid residues in length.
- 53. (Previously Presented) The protein of claim 51 which further comprises a polypeptide sequence heterologous to the HHEPU32 cDNA contained in ATCC Deposit No. 209603.
- 54. (Previously Presented) A composition comprising the protein of claim 51 and an acceptable carrier.
- 55. (Previously Presented) An isolated protein produced by the method comprising:
  - (a) expressing the protein of claim 51 by a cell; and
  - (b) recovering said protein.
- 56. (Currently Amended) An isolated protein comprising amino acid residues [[1]] 19 to 153 of SEQ ID NO: 108.
- 57. (Previously Presented) The isolated protein of claim 56 which comprises amino acid residues 2 to 153 of SEQ ID NO: 108.
- 58. (Currently Amended) The isolated protein of claim 56 which comprises amino acid residues [[19]] 1 to 153 of SEQ ID NO: 108.

59. (Previously Presented) The protein of claim 56 which further comprises a polypeptide sequence heterologous to SEQ ID NO: 108.
60. (Previously Presented) A composition comprising the protein of claim 56 and an acceptable carrier.
61. (Previously Presented) An isolated protein produced by the method comprising:  
(a) expressing the protein of claim 56 by a cell; and  
(b) recovering said protein.
62. (Previously Presented) An isolated first polypeptide at least 90% identical to a second polypeptide consisting of amino acid residues 1 to 153 of SEQ ID NO: 108.
63. (Previously Presented) The isolated polypeptide of claim 62, wherein said first polypeptide is at least 95% identical to said second polypeptide.
64. (Currently Amended) The ~~protein~~ isolated polypeptide of claim 62 which further comprises a polypeptide sequence heterologous to SEQ ID NO: 108.
65. (Currently Amended) A composition comprising the ~~protein~~ isolated polypeptide of claim 62 and an acceptable carrier.
66. (Currently Amended) An isolated protein produced by the method comprising:  
(a) expressing the ~~protein~~ isolated polypeptide of claim 62 by a cell; and  
(b) recovering said protein.
67. (Previously Presented) An isolated protein consisting of a fragment of SEQ ID NO:108, wherein said fragment is at least 30 contiguous amino acid residues in length.

68. (Previously Presented) The isolated protein of claim 67, wherein said fragment is at least 50 contiguous amino acid residues in length.
69. (Previously Presented) The protein of claim 67 which further comprises a polypeptide sequence heterologous to SEQ ID NO: 108.
70. (Previously Presented) A composition comprising the protein of claim 67 and an acceptable carrier.
71. (Previously Presented) An isolated protein produced by the method comprising:
- (a) expressing the protein of claim 67 by a cell; and
  - (b) recovering said protein.